Mantle Cell Lymphoma
Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Leah SherwoodMantle Cell Lymphoma | November 2, 2022
Regulatory applications were filed for epcoritamab to treat R/R LBCL, DLBCL
Read More
Leah SherwoodMantle Cell Lymphoma | October 17, 2022
Jia Ruan, spoke on emerging treatment options for MCL in this interview from SOHO 2022.
Cecilia BrownMantle Cell Lymphoma | October 13, 2022
Mantle cell lymphoma (MCL) is associated with a poor prognosis and is rarely curable with currently available standard ...
Cecilia BrownMantle Cell Lymphoma | October 13, 2022
The U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the TakeAim Lymphoma phase I/II study of ...
Kerri FitzgeraldMantle Cell Lymphoma | October 5, 2022
Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future.
Leah SherwoodMantle Cell Lymphoma | October 5, 2022
Tycel Phillips, MD, discusses the role of targeted therapies in frontline mantel cell lymphoma (MCL).
Leah SherwoodMantle Cell Lymphoma | October 5, 2022
Jia Ruan, MD, PhD, discusses emerging treatment options for mantle cell lymphoma at the 2022 SOHO Annual Meeting.
Leah SherwoodMantle Cell Lymphoma | October 5, 2022
The phase III BRUIN MCL-321 is currently enrolling patients to compare the efficacy of pirtobrutinib versus other Bruton’s ...
Leah SherwoodMantle Cell Lymphoma | October 5, 2022
Updated results from a phase I/IIb study demonstrated promising efficacy for the novel agent pirtobrutinib in heavily ...
Leah SherwoodChronic Lymphocytic Leukemia | August 16, 2022
The U.S. Food and Drug Administration (FDA) has approved the new tablet formulation of acalabrutinib for all current ...
Kerri FitzgeraldChronic Lymphocytic Leukemia | June 14, 2022
The phase I/II study included patients with relapsed/refractory CLL or MCL who received two or more prior systemic therapies.
Kerri FitzgeraldTransplantation & Cellular Therapy | June 6, 2022
Median PFS and OS were 25.8 months (95% CI, 9.6-47.6) and 46.6 months (95% CI, 24.9-not estimable), respectively.
Leah LawrenceTransplantation & Cellular Therapy | March 2, 2022
With increasing evidence of efficacy as front-line treatment in relapsed/refractory disease, clinicians are excited to see ...
Sabrina AhleMantle Cell Lymphoma | March 2, 2022
A recent study of brexu-cel supports its use for the treatment of patients with relapsed or refractory mantle cell lymphoma ...
Ariel DeMaioAggressive B-Cell Lymphoma | March 2, 2022
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Sabrina AhleMyeloma | February 22, 2022
Patients with hematologic malignancies have a significantly higher rate of composite thrombotic outcomes during acute ...
Sabrina AhleAcute Lymphoblastic Leukemia | February 8, 2022
Researchers have discovered that chemotherapy and COVID-19 infection cause neuro-inflammation in similar ways.
Sagar Lonial, MD, FACPMyeloma | February 2, 2022
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Susan O'Brien, MDAcute Lymphoblastic Leukemia | February 1, 2022
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Rebecca AraujoMantle Cell Lymphoma | November 15, 2021
Patients in the trial were treated for lymphoma, leukemia, or multiple myeloma.
Advertisement
Editorial Board

Advertisement